Exosome Diagnostics Completes $27M First Close of Series B
March 12, 2014
Exosome Diagnostics, a developer of biofluid-based molecular diagnostic tests for oncology, neurodegenrative diseases and other clinical areas, has raised $27 million in Series B funding led by QIAGEN and Arcus Ventures, with participation from Tiger Partners, CD Ventures and Monashee Capital, as well as existing investors NGN Capital and Forbion Capital Partners. The company, which previously raised $20 million of Series A funding at a valuation of $32 million in 2010, will use proceeds from the new round to launch its first clinical product in the U.S., advance development of multiple commercial programs and continue R&D of its technology platform. In conjunction with the transaction, Arcus Ventures' Steven Soignet will join Exosome's Board of Directors.